Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Breast Cancer Res Treat. 2014 Dec 10;149(1):69–79. doi: 10.1007/s10549-014-3201-6

Fig. 2. P7170 decreases proliferation and viability of ER+ breast cancer cells.

Fig. 2

A) Cells were treated in triplicate with 0-30 nM P7170 for 5-8 days, then analyzed by SRB assay to quantify relative numbers of adherent cells. FR cells were treated in the presence of 1 μM fulvestrant. LTED cells were treated in hormone-depleted medium. Relative cell numbers were used to calculate inhibitory effect. IC50 values are indicated by dotted lines. B) Cells were treated in triplicate ± 1 μM fulvestrant and 200 nM P7170 for 3-4 days. Fractions of apoptotic cells were determined by Annexin-V/propidium iodide labeling followed by flow cytometry. Mean + SEM is shown. *p≤0.05 by Bonferroni post-hoc test vs. control, unless otherwise indicated by brackets.